Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
Public ClinicalTrials.gov record NCT03061812. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this randomized, open-label, 2-arm, phase 3 study is to assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic SCLC with high levels of DLL3, who have first disease progression during or following front-line platinum-based chemotherapy.
Study identification
- NCT ID
- NCT03061812
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 444 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2017 (Actual)
- Primary completion
- Feb 12, 2020 (Actual)
- Completion
- Feb 12, 2020 (Actual)
- Last update posted
- Feb 23, 2021
2017 – 2020
United States locations
- U.S. sites
- 31
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute /ID# 155873 | Huntsville | Alabama | 35805 | — |
| Mitchell Cancer Institute /ID# 158151 | Mobile | Alabama | 36604 | — |
| Carti /Id# 156982 | Little Rock | Arkansas | 72205 | — |
| Highlands Oncology Group /ID# 155902 | Springdale | Arkansas | 72762 | — |
| Cedars-Sinai Medical Center /ID# 157102 | Beverly Hills | California | 90211 | — |
| Moore UC San Diego Cancer Center /ID# 156965 | La Jolla | California | 92093 | — |
| Los Angeles Hematology Oncolog /ID# 155879 | Los Angeles | California | 90017 | — |
| University of California, Davis Comprehensive Cancer Center /ID# 157001 | Sacramento | California | 95817 | — |
| St Jude Hospital dba St Joseph /ID# 155899 | Santa Rosa | California | 95403 | — |
| Icri /Id# 157090 | Whittier | California | 90603 | — |
| Christiana Care Health Service /ID# 158171 | Newark | Delaware | 19713 | — |
| Cancer Specialists of North Florida - Southpoint /ID# 155828 | Jacksonville | Florida | 32256 | — |
| Georgia Cancer Center /ID# 160206 | Atlanta | Georgia | 30342 | — |
| St. Luke's Mountain States Tumor Institute - Meridian /ID# 164550 | Meridian | Idaho | 83712 | — |
| NorthShore University HealthSystem - Evanston Hospital /ID# 157054 | Evanston | Illinois | 60201 | — |
| Ingalls Memorial Hosp /ID# 155871 | Harvey | Illinois | 60426 | — |
| Goshen Center for Cancer Care /ID# 155946 | Goshen | Indiana | 46526 | — |
| University of Louisville /ID# 155947 | Louisville | Kentucky | 40202 | — |
| Ochsner Clinic Foundation /ID# 160807 | Baton Rouge | Louisiana | 70836-6455 | — |
| Dana-Farber Cancer Institute /ID# 160210 | Boston | Massachusetts | 02215 | — |
| Sparrow Regional Cancer Center, Sparrow Health System /ID# 157021 | Lansing | Michigan | 48912 | — |
| Nebraska Hematology Oncology /ID# 155900 | Lincoln | Nebraska | 68506 | — |
| Gabrail Cancer Center Research /ID# 155920 | Canton | Ohio | 44718 | — |
| Oregon Health and Science University /ID# 157055 | Portland | Oregon | 97239 | — |
| UPMC Hillman Cancer Ctr /ID# 164403 | Pittsburgh | Pennsylvania | 15232 | — |
| Univ Medical Ctr Brackenridge /ID# 156967 | Austin | Texas | 78701 | — |
| UT Southwestern Medical Center /ID# 158150 | Dallas | Texas | 75390-7208 | — |
| University of Vermont Medical Center /ID# 162317 | Burlington | Vermont | 05401-1473 | — |
| University of Washington /ID# 162626 | Seattle | Washington | 98109 | — |
| Medical Oncology Associates /ID# 156856 | Spokane | Washington | 99208 | — |
| West Virginia Univ School Med /ID# 155872 | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 164 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03061812, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03061812 live on ClinicalTrials.gov.